Document:

Consulting Agreement between Cancer Genetics, Inc. and Louis Malone

 Exhibit 10.11 
 CONSULTING AGREEMENT 
 THIS CONSULTING
AGREEMENT (this “Agreement”), dated as of this 10th day of June, 2010, by and between Cancer Genetics, Inc., a Delaware corporation (the “Company”) and Louis J. Maione (the “Consultant”). The Company and the Consultant shall sometimes
be referred to herein individually, as a “Party” and collectively, as the “Parties”. 
 WITNESSETH:

 WHEREAS, the Company is in the business of developing and marketing esoteric cancer tests; 

WHEREAS, the Consultant is a former executive of the Company and is experienced in providing legal and business counsel in
laboratory related operations; 
 WHEREAS, the Company believes that the Consultant’s skills are beneficial to the
Company; and 
 WHEREAS, the Company desires to retain the Consultant for (i) transition issues related to the
Company’s probe operations and (ii) the pending claim related to the Massachusetts matter. 
 NOW, THEREFORE,
in consideration of the mutual covenants and the premises herein set forth, the Company and the Consultant hereby agree as follows: 
 1. Consulting Relationship. During the Term (as defined herein), the Consultant will provide consulting services (the “Services”) to the Company as the Chairman of the Board of Directors
of the Company may from time-to-time reasonably direct in accordance only with the two matters enumerated on Exhibit A appended hereto. 
 (a) Anything to the contrary notwithstanding, while the Consultant is not required hereunder to expend any specific number of hours in connection with his consultancy, the Consultant shall not be
obligated to consult for more than One Hundred and Twenty-five hours (125) in the aggregate during the stated term, which includes travel time, portal to portal, approved by the Company in advance. Thereafter, should the threshold of 125 hours
be met at any time during the term, and the parties wish to continue the arrangement contemplated by this agreement after the 125 hours have been expended, the Consultant shall be compensated at the rate of Four Hundred Dollars ($400.00) per hour,
billable to the nearest tenth of an hour. 
 (b) The Consultant shall provide the Company with time records, including a
reasonable explanation of the activity for which the Consultant expended the time, which shall be billed to the nearest tenth of an hour, within ten (10) business days of the close of each month. 

2. Term. The term of this Agreement (the “Term”) shall begin on the date first set forth above and shall continue for
one year unless the Consultant is terminated 

  
 1 

 
pursuant to Section 5 below. Following the expiration of the Term, all of the Company’s obligations under this Agreement shall automatically and immediately cease and terminate, except
for its obligation to pay the Consultant compensation earned prior to the date of the termination and except as otherwise specifically provided in this Agreement. 
 3. Obligations of the Consultant. The Consultant shall perform the Services faithfully and to the best of the Consultant’s ability. The Consultant shall devote the time necessary to perform
the Services, as reasonably determined by the Board of Directors of the Company; provided, however, that the Consultant shall be free to engage in outside activities that do not interfere with the performance of his duties under this
Agreement. 
 4. Compensation. In consideration for the Services to be provided by the Consultant and other obligations,
the Company agrees to provide compensation to the Consultant as follows: 
 (a) Cash Payments. During the Term, the
Consultant shall receive $12,500 of compensation per calendar quarter payable on the last day of each calendar quarter. Unless otherwise agreed upon in writing by the Company, the Company’s maximum liability for all Services performed during
the Term shall not exceed $50,000. The quarterly compensation of the Consultant shall be reviewed on a quarterly basis by the Board of Directors in its sole discretion, taking into consideration, among other things, the status of the projects on
which the Consultant has provided assistance, and such other factors as the Board of Directors deems relevant. 
 (b) Reimbursement of
Expenses. During the Term, the Company shall reimburse the Consultant for the Consultant’s reasonable business expenses, within twenty (20) days of submission to the Company, incurred in the performance of the Consultant’s duties
under this Agreement; provided, however, that such expenses are verified by written receipts or invoices if and to the extent required by the Board of Directors. Expenses shall include, by way of example and not limitation, all travel
expenses, including gas and tolls, food, lodging, and other transportation costs. Any air travel of over four (4) hours in duration, whether domestic or international, shall be at “business travel accommodations.” 

(c) Fringe Benefits. The Consultant acknowledges and agrees that the Consultant will not be eligible for any Company employee
benefits. To the extent the Consultant otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, the Consultant hereby expressly declines to participate in such Company employee benefits. 

5. Termination. The Services shall be performed on an “at will” basis and this Agreement shall be terminable at any time
by the Company or the Consultant, for any reason or for no reason, upon ten (10) days written notice. Nothing contained in this Agreement shall be interpreted or construed to create or imply any obligation of the Company to continue this
Agreement for any particular length of time or duration and the Consultant acknowledges that no one has made any representations or assurances to the Consultant regarding the length or duration of his/her employment with the Company. 

  
 2 

 6. Payments upon Termination. If this Agreement is terminated pursuant to
Section 5, the Consultant shall be entitled to receive a prorata portion of unpaid compensation for the calendar quarter. Upon Termination, such payment shall be payable to Consultant ten (10) days after Termination. 

7. Independent Contractor. The Consultant’s relationship with the Company will be that of an independent contractor and not
that of an employee. 
 (a) Method of Provision of Services. The Consultant shall work from his residence or other place
of business and shall not perform any services from the Company’s office location unless requested by the Chairman. The Consultant, while employed by the Company, executed a Proprietary Information and Invention Assignment Agreement attached to
this Agreement as Exhibit B (the “Proprietary Information and Invention Assignment Agreement”). The Consultant agrees the Proprietary Information and Invention Assignment Agreement remains in full force and effect during the term of
this Agreement. 
 (b) No Authority to Bind Company. The Consultant has no authority to enter into contracts that bind
the Company or create obligations on the part of the Company without the prior written authorization of the Company. 
 (c)
Withholding; Indemnification. The Consultant shall have full responsibility for applicable withholding taxes for all compensation paid to the Consultant, its partners, agents or its employees under this Agreement, and for compliance, with all
applicable labor and employment requirements with respect to the Consultant’s self-employment, sole proprietorship or other form of business organization, and Consultant’s partners, agents and employees, including state worker’s
compensation insurance coverage requirements and any Federal immigration visa requirements. The Consultant agrees to indemnify, defend and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to
such withholding taxes, labor or employment requirements, including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to the Consultant or the
Consultant’s partners, agents or its employees. 
 8. Consulting or Other Services for Competitors. The Consultant
represents and warrants that the Consultant does not presently perform or intend to perform, during the Term, consulting or other services for, or engage in or intend to engage in an employment relationship with, companies who businesses or proposed
businesses in any way involve products or services which would be competitive with the Company’s products or services, or those products or services proposed or in development by the Company during the term of the Agreement (except for those
companies, if any, listed on Exhibit C attached hereto). If, however, the Consultant decides to do so, the Consultant agrees that, in advance of accepting such work, the Consultant will promptly notify the Company in writing, specifying the
organization with which the Consultant proposes to consult, provide services, or become employed by and to provide information sufficient to allow the Company to determine if such work would conflict with the terms of this Agreement,

  
 3 

 
including the terms of the Proprietary Information and Invention Assignment Agreement, the interests of the Company or further services which the Company might request of the Consultant. If the
Company determines that such work conflicts with the terms of this Agreement, the Company reserves the right to terminate this Agreement immediately. 
 9. Insurance on Consultant. The Company shall be entitled to obtain and maintain, at the Company’s expense, key person life insurance on the life of the Consultant, naming the Company as the
beneficiary of such policy. The Consultant agrees to cooperate with the Company and take all reasonable actions necessary to obtain such insurance, such as taking the usual and customary physical examinations and providing true and accurate
personal, health related information for any application at no cost to the Consultant. 
 10. Proprietary Information and
Invention Assignment Agreement. If there is any conflict between the terms of the Proprietary Information and Invention Assignment Agreement and the terms of this Agreement, the terms of this Agreement shall prevail. 

11. Assignment. This Agreement is personal to each of the Parties, and neither Party may assign nor delegate any of that
Party’s rights or obligations under this Agreement without first obtaining the written consent of the other Party, except that the Company may assign and delegate its rights and obligations under this Agreement to a legal successor to the
Company or assignee whose management and ownership remains unchanged from that of the Company. 
 12. Notices. All
notices required under this Agreement shall be given by personal delivery, facsimile, email or by mailing, via certified or registered mail, return receipt requested, addressed to the Company or to the Consultant as follows: 

If to the Company to: 
 Cancer Genetics, Inc. 
 Attn: Chairman 

201 Route 17 North, 2nd Floor 
 Rutherford, NJ 07675 
 Fax: (201) 263-1328 

Email: chagantr@mskcc.org 
 If to the Consultant to: 
 Mr. Louis J. Maione 

850 Park Avenue, 10B 
 New York, New York 10075 
 Email: louisjmaione3@gmail.com 

If sent by mail, such notice shall be deemed to have been given on the date set forth on receipt of the registered or certified mail or upon the third
day after mailing, whichever is earlier. Addresses may be changed only by giving written notice thereof, via registered or certified mail, to the other Party. 
 13. Expenses of Enforcement. In the event that any suit or legal proceeding is brought to enforce any provision of this Agreement, the prevailing Party in such suit or

  
 4 

 
proceeding shall be entitled to receive all of such Party’s reasonable expenses, including reasonable attorneys’ fees and costs. 

14. Miscellaneous. 
 (a) This Agreement shall be governed by and construed exclusively in accordance with the laws of the State of New Jersey without giving effect to any choice or conflict of law rules to the contrary.

 (b) Should any provision of this Agreement be held invalid or unenforceable, the remainder of this Agreement shall not be
affected and shall be enforceable to the fullest extent permitted at law or in equity. 
 (c) This Agreement contains the entire
agreement between the Parties concerning the subject matter hereof and supersedes all prior conversations, proposals, negotiations, understandings, and agreements, whether written or oral concerning the subject matter hereof. 

(d) This Agreement shall not be amended, altered, changed, modified, supplemented, or rescinded in any manner except by written agreement
executed by both Parties expressly referring to this Agreement. 
 (e) Any one or more waivers of a breach of a covenant or
condition by either Party shall not be construed as a waiver of a subsequent breach of the same covenant or condition. 
 (f)
The rights and obligations under this Agreement shall survive the termination of the Consultant’s service to the Company in any capacity and shall be binding upon the Consultant and the successors and assigns of the Company. 

[Signature Page to Follow] 

  
 5 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date first set
forth above. 
  

			
	CANCER GENETICS, INC.
		
	By:	 	     /s/ Raju S.K. Chaganti

		 	    Name: Raju S.K. Chaganti
		 	    Title: Chairman

  

	
	CONSULTANT
	
	 /s/ Louis J. Maione

	Louis J. Maione

  
 6 

 EXHIBIT A 

DESCRIPTION OF CONSULTING SERVICES 
 Consultant will provide consulting services as follows: 
  

	 	•	 	 Assistance and consultation with regard to the international distribution of probes, including interfacing with all distributors, Techno genetics/Bouty
personnel, professionals on behalf of Cancer Genetics Italia, S.r.l., where required, by management of the Company. 

  

	 	•	 	 Legal Consultancy regarding the pending DOJ claim related to the operations of the Company laboratory when located in Massachusetts, including
interfacing with Company counsel, the Company’s indemnity carriers, and the Board of Directors. 

  
 7 

 EXHIBIT B 

PROPRIETARY INFORMATION AND 
 INVENTION ASSIGNMENT AGREEMENT 

  
 8 

 EXHIBIT C 

LIST OF COMPANIES 
 EXCLUDED UNDER SECTION 8 
          No
conflicts 
          Additional Sheets Attached 

 

			
	Signature of Consultant:	 	 /s/ Louis J. Maione

  

			
	Print Name of Consultant:	 	Louis J. Maione

  

			
	Date:	 	June 10, 2010

  
 9Termination Agreement

 Exhibit 10.12 
 Cancer Genetics, Inc. 
 201 Route 17 North, 2nd Floor 

Rutherford, NJ 07675 

June 10, 2010 
 Mr. Louis J. Maione

 850 Park Avenue, 10B 
 New York, New
York 10075 
  

	 	Re:	Termination of Employment 

 Dear Lou:

 In connection with the termination of your employment by Cancer Genetics, Inc. (the “Company”) as of June 10,
2010 (the “Termination Date”), you will be provided with the benefits described below in consideration for your execution of this agreement (this “Agreement”). 

1. (a) Benefits Continuation. If you would like to do so, you may make an election pursuant to the law known as COBRA, 29
U.S.C. Section 1161 et seq, to continue receiving the group health insurance which the Company currently offers to its employees. You will be solely responsible for the payment of any premiums associated with an election under COBRA.

 (b) Payment to Closing. On the 11th day after execution of this Agreement without revocation (June 21, 2010, the
“Closing Date”), the Company shall pay to you by wire transfer of immediately available funds to an account designated by the Seller a total sum of $120,000.00 (the “Settlement Amount”). 

2. Employee Release. In exchange for the execution of this Agreement and other good and valuable consideration, and except as
contemplated by this Section 2, you hereby fully, forever, irrevocably and unconditionally release and discharge the Company, and any subsidiary or affiliated organization of the Company and their current or former officers, directors,
stockholders, corporate affiliates, attorneys or employees (the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suit, rights, debts, sums of money, (including the promissory note by and
between the Company and you, dated December 27, 2006), costs, accounts, covenants, contracts, agreements, promises, omissions, damages, obligations, liabilities and expenses (including attorneys’ fees and costs), of every kind and nature,
known or unknown, which you ever had or now have against the Released Parties, including, but not limited to, all claims arising out of your employment (including, but not limited to, your employment agreement with the Company dated October 21,
2009), all claims arising out of your separation from employment, all claims related to the note agreement between you and the Company issued in December 2006, all claims arising from any failure to re-employ you, all claims and damages relating to
race, sex, national origin, handicap, religious, sexual orientation, benefits and age discrimination, all employment discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. Section 2000 et. seq., the Age Discrimination
in Employment Act, 29 U.S.C. Section 1001, et. seq., and the Americans with Disabilities Act, 42 U.S.C. Section 12101 et. seq., and similar state or local 

  
 1 

 
statutes, all wrongful discharge claims, common law tort, defamation, breach of contract and other common law claims and any claims under any other federal, state or local statutes not expressly
referenced above. Excluded from the scope of this Agreement is (i) any claim or right by you under any policy or policies of directors and officers liability insurance maintained by the Company as in effect from time to time; and (ii) any
right of or for indemnification pursuant to your guaranty of lease obligations of the Company as listed on Exhibit B. 
 3.
Company Release. In exchange for your execution of this Agreement and other good and valuable consideration, the Company hereby fully, forever irrevocably and unconditionally releases and discharges you from any and all claims, charges,
complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, covenants, contracts, agreements, promises, omissions, damages, obligations, liabilities and expenses (including attorney’s fees and costs),
of every kind and nature, known or unknown, which the Company ever had or now have against you; provided, however, that the release will not discharge you from any matters which might arise from your employment relationship with the
Company, to the extent that the same were the result of (i) fraud, (ii) a crime involving moral turpitude or dishonesty, or (iii) a violation of Federal, State or local statutes or administrative regulation, provided, however, that
such violation would have an adverse impact on the Company as determined by a trier of fact in any trial or proceeding (“Excluded Matters”). As of date of this Agreement, the Company does not have any actual knowledge of an Excluded
Matter. 
 4. Return of Property. By signing below, you agree that you will, on the Closing Date, immediately return to
the Company, any documents (including electronic documents, disks and files) that you received and/or created as part of your employment with the Company and that remain in your possession, custody or control, and you further agree that you have not
retained (yourself or through an agent) any copies thereof. You further agree that you will, on or before the Closing Date, return all tangible property of the Company that remains in your possession, custody or control; including but not limited
to, the 2008 Acura RL, including keys and registration, Company sponsored credit cards and/or calling cards, keys, and any other Company property. You agree and understand that your compliance with the requirements of this Section 4 is an
express condition to your entitlement to receive the benefits contemplated by Section 1 of this Agreement. Upon your delivery to the Company of an executed copy of this Agreement, the Company shall return to you any stamps which bear your
signature. Any stamps which reference the Company, as well your signature, shall be destroyed by the Company. 
 5.
Confidentiality. You shall keep the terms and conditions of this Agreement strictly confidential. You shall not disclose the terms of this Agreement to anyone, except your tax and/or legal advisors. 

6. Nature of Agreement. You and the Company understand and agree that this Agreement is a termination and settlement agreement and
does not constitute an admission of liability or wrongdoing on the part of you, the Company, or any other person. 
 7.
Amendment. This Agreement shall be binding upon the parties hereto and may not be modified in any manner, except by a written instrument signed by the parties hereto. This agreement is binding upon and shall inure to the benefit of the
parties hereto and their respective agents, assigns, estates, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any occasion. 
 8. Validity. Should any provision of this Agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or

  
 2 

 
provisions shall not be affected thereby and such illegal and invalid part, term or provision shall be deemed not to be a part of this Agreement. 

9. Nondisparagement. You and the Company agree to refrain from directly, or indirectly, making any disparaging remarks about the
other party, it attorneys and employees. “Disparaging remarks” shall mean the publication of a matter that is untrue. In the event the Company is contacted to provide any employment reference for you, it shall advise the inquiring party of
your job title, job description and dates of employment and that it is against the policy of the Company to provide any additional information. 
 10. Entire Agreement; Applicable Law; Remedies. This Agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your termination benefits
and settlement of claims against the Company and cancels all previous oral and written negotiations, agreements, commitments and writings in connection therewith. This Agreement shall be governed by the laws of the State of New Jersey to the extent
not preempted by federal law. In the event of a breach of any provision of this Agreement and General Release, either party may institute an action specifically to enforce any term or terms of this Agreement and General Release and/or seek any
damages for breach. 
 11. Acknowledgments and Affirmations. You acknowledge and affirm that: 

(a) All vacation pay was taken to date and a balance of zero vacation hours remain; 

(b) You have not filed, caused to be filed, and you are not presently a party to any claim against any Released Party; 

(c) You have been paid and/or have received all compensation, wages, bonuses, commissions, and/or benefits to which you are entitled;

 (d) You have been granted any leave to which you were entitled under the Family and Medical Leave Act (or related state or
local leave laws) and disability accommodation laws; 
 (e) You have no known workplace injuries or occupational diseases; and

 (f) You have not been retaliated against for reporting any allegations of wrongdoing by Cancer Genetics, Inc. or its
officers, including any allegations of corporate fraud. 
 12. Compliance With Agreement. You agree and understand that
your compliance with the requirements of this Agreement is an express condition to your entitlement to receive the Settlement Amount. You agree and acknowledge that you would not receive the monies and/or benefits specified in Section 1 of this
Agreement, except for your execution of this Agreement and General Release and the fulfillment of the promises contained herein. 
 13. Post Closing Deliverables. You agree that immediately upon closing and receipt of the Settlement Amount, you will mark as “paid in full” and return to the Company the original note
agreement between you and the Company issued in December 2006. 
 14. Successors and Assigns. This Agreement shall be
binding upon and inure to the benefit of the parties successors and assigns. 

  
 3 

 15. Transfer of Securities. The Company hereby represents and warrants to you that
all actions, if any, necessary to enable you to transfer the common stock and the option shares (after giving effect to the exercise of the options) in accordance with the terms and conditions of the Stock Purchase Agreement have been taken and
remain in full force and effect. 
 YOU ARE ADVISED THAT YOU HAVE HAD UP TO TWENTY-ONE (21) CALENDAR DAYS TO CONSIDER THIS AGREEMENT AND
GENERAL RELEASE. 
 YOU MAY REVOKE THIS AGREEMENT AND GENERAL RELEASE FOR A PERIOD OF SEVEN (7) CALENDAR DAYS FOLLOWING THE DAY YOU
SIGN THIS AGREEMENT AND GENERAL RELEASE. ANY REVOCATION WITHIN THIS PERIOD MUST BE SUBMITTED, IN WRITING, TO CANCER GENETICS, INC. TO THE ATTENTION OF RAJU S.K. CHAGANTI, CHAIRMAN AND STATE, “I HEREBY REVOKE MY ACCEPTANCE OF OUR AGREEMENT AND
GENERAL RELEASE.” THE REVOCATION MUST BE PERSONALLY DELIVERED TO RAJU S.K. CHAGANTI, CHAIRMAN OR HIS DESIGNEE, OR MAILED TO RAJU S.K. CHAGANTI, CHAIRMAN AND POSTMARKED WITHIN SEVEN (7) CALENDAR DAYS AFTER YOU SIGN THIS AGREEMENT AND
GENERAL RELEASE. 
 YOU AGREE THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT AND GENERAL RELEASE, DO NOT RESTART
OR AFFECT IN ANY MANNER THE ORIGINAL CONSIDERATION PERIOD. 
 YOU FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTER INTO THIS
AGREEMENT AND GENERAL RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS YOU HAVE OR MIGHT HAVE AGAINST THE RELEASED PARTIES. 

YOU ACKNOWLEDGE THAT YOU HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY OF YOUR OWN CHOOSING PRIOR TO EXECUTING THIS AGREEMENT. 

YOU AFFIRM THAT NO OTHER PROMISES OR AGREEMENTS OF ANY KIND HAVE BEEN MADE TO YOU BY ANY PERSON OR ENTITY TO CAUSE YOU TO SIGN THIS AGREEMENT, AND
THAT YOU FULLY UNDERSTAND THE MEANING AND INTENT OF THIS AGREEMENT. YOU REPRESENT AND WARRANT THAT YOU HAVE HAD AN OPPORTUNITY TO FULLY DISCUSS AND REVIEW THE TERMS OF THIS AGREEMENT WITH AN ATTORNEY OF YOUR OWN CHOOSING PRIOR TO EXECUTING THIS
AGREEMENT. YOU FURTHER REPRESENT THAT YOU HAVE CAREFULLY READ THIS AGREEMENT, UNDERSTAND THE CONTENTS HEREIN, AND FREELY AND VOLUNTARILY ASSENT TO ALL OF THE TERMS AND CONDITIONS SET FORTH HEREIN. 

(Signature Page to Follow) 

  
 4 

 If you are in agreement with the terms and conditions set forth above, please sign below. 

 

			
		 	Very truly yours,
		
		 	CANCER GENETICS, INC.
		
	By:	 	 /s/ Raju S.K. Chaganti

		 	Name: Raju S.K. Chaganti
		 	Title:   Chairman

 I hereby agree to the terms and conditions set forth above and I have chosen to execute this Agreement on the date
below. I intend that this Agreement become a binding agreement between me and the Company. 
  

	
	 /s/ Louis J. Maione

	Louis J. Maione
	
	Dated: June 10, 2010

  
 5 

 EXHIBIT A 
 June 21, 2010 
 Mr. Raju S.K. Chaganti, Chairman 

Cancer Genetics, Inc. 
 201
Route 17 North, 2nd Floor 

Rutherford, NJ 07675 
  

	 	Re:	Agreement and General Release 

 Dear
Dr. Chaganti: 
 On June 10, 2010, I signed an Agreement and General Release between Cancer Genetics, Inc. and me. I
was advised in writing by Cancer Genetics, Inc. to consult with an attorney of my choosing, prior to executing this Agreement and General Release. 
 More than seven (7) calendar days have elapsed since I executed the above-mentioned Agreement and General Release. I have not revoked my acceptance or execution of that Agreement and General Release
and hereby reaffirm my acceptance of that Agreement and General Release up through the date of this letter. 
  

	
	Very truly yours,
	
	 /s/ Louis J. Maione

	Louis J. Maione

  
 6 

 EXHIBIT B 
 Lease Obligation of the Company – Guaranteed by Louis J. Maione 
  

	1.	Lease for Office with Meadows Office, L.L.C. dated October 7, 2007. 

  

	2.	Lease for lab equipment described below: 

  

	 	a.	HGF 110407-5 Microarray scanner bundle from Agilent Technologies 

  

	 	b.	HGF 110407-6 Office furniture and equipment 

  

	 	c.	HGF 050409-7 Cytology/Histology equipment from Leica 

  
 7 

 EXHIBIT C 
 June 10, 2010 
 Mr. Raju S.K. Chaganti, Chairman 

Cancer Genetics, Inc. 
 201
Route 17 North, 2nd Floor 

Rutherford, NJ 07675 
  

	 	Re:	Resignation 

 Dear Dr. Chaganti:

 Effective simultaneously with the Closing Date of the Agreement and General Release between Cancer Genetics, Inc. and me, I
hereby resign as an officer and director or Cancer Genetics, Inc., and each of its subsidiaries. 
  

	
	Very truly yours,
	
	 /s/ Louis J. Maione

	Louis J. Maione

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]